Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in foveolar cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 152 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 7300
Sealed predictions
- SOX21 in dopamine neurons, braak+0.05 (p 0.893) → +0.15 (p 0.702)receipt 7309
- SOX21 in oligodendrocytes, braakn/a → n/areceipt 7308
Swarm cases
receipt 7309: SOX21 in dopamine neurons, braak
- power
- full sample +0.03 (p 0.894, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.19 (p 0.450, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.16 (p 0.521, n 18). could be the mix.
- skeptic
- leave-one-out range -0.05 to +0.14, sign flips 5; without severely affected donors +0.03 (p 0.894, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SOX21 in dopamine neurons.
case closed: nothing better to follow up.
receipt 7308: SOX21 in oligodendrocytes, braak
- cell type
- SOX21 is not measured in oligodendrocytes; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SOX21 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts